Entering text into the input field will update the search result below

Merger Arbitrage Mondays: Merck Acquires Acceleron For $10.8 Billion

Summary

  • Merck acquires Acceleron for $180 per share in cash.
  • Amicus Therapeutics to launch a genetic medicine company, Caritas Therapeutics through a business combination agreement with ARYA Sciences Acquisition Corp IV.
  • Five9 and Zoom Video Communications mutually terminate their merger agreement.
Glass bottles in production in the tray of an automatic liquid dispenser, a line for filling medicines against bacteria and viruses, antibiotics and vaccines

aleksejplatonov/iStock via Getty Images

The third quarter of 2021 was an active one for M&A with 52 new deals announced, amounting to more than $207 billion. Third quarter M&A activity however did not eclipse what we saw in the prior quarter with 59 new deals announced in

This article was written by

Asif Suria profile picture
9.67K Followers
Comprehensive tools and detailed analysis for event-driven investors

I am an entrepreneur and investor with a focus on event driven strategies including merger arbitrage, spinoffs, (legal) insider trading, buybacks and SPACs. I was one of the earliest contributors on Seeking Alpha and started publishing here in 2005. For more than a decade I have been writing every week about M&A and interesting insider transactions. My work has been mentioned in Barron's, Dow Jones, BNN Bloomberg and other publications.  

I have been an active investor for more than two decades and my background in technology has helped me built tools that inform my investing process, especially as it relates to event-driven strategies that require updated data and processes. The focus on my Inside Arbitrage service is to provide investors with the right combination of tools and analysis to help them take advantage of strategies that can perform well across market cycles.  

Analyst’s Disclosure: I/we have a beneficial long position in the shares of NUAN, CHNG, TRIL either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.

Disclaimer: I have long positions in Nuance Communications (NUAN), Change Healthcare (CHNG) and Trillium Therapeutics (TRIL). I also have put options in Change Healthcare. Please do your own due diligence before buying or selling any securities mentioned in this article. We do not warrant the completeness or accuracy of the content or data provided in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.